Literature DB >> 12463763

Stem cells for neurodegenerative disorders: where can we go from here?

Janel E Le Belle1, Clive N Svendsen.   

Abstract

The use of stem cells in cell replacement therapy for neurodegenerative diseases has received a great deal of scientific and public interest in recent years. This is due to the remarkable pace at which paradigm-changing discoveries have been made regarding the neurogenic potential of embryonic, fetal, and adult cells. Over the last decade, clinical fetal tissue transplants have demonstrated that dopaminergic neurons can survive long term and provide functional clinical benefits for patients with Parkinson's disease. Pluripotent embryonic stem cells and multipotent neural stem cells may provide renewable sources that could replace these primary fetal grafts. Considerable advancement has been made in generating cultures with high numbers of neurons in general and of dopaminergic neurons using a varied array of techniques. However, much of this encouraging progress still remains to be tested on long-term expanded human cultures. Further problems include the low survival rate of these cells following transplantation and the tumorigenic tendencies of embryo-derived cells. However, pre-differentiation or genetic modification of stem cell cultures prior to transplantation may help lead to the generation of high numbers of cells of the desired phenotype following grafting. Boosting particular factors or substrates in the culture media may also protect grafted neurons from oxidative and metabolic stress, and provide epigenetic trophic support. Possible endogenous sources of cells for brain repair include the transdifferentiation of various types of adult cells into neurons. Despite the excitement generated by examples of this phenomenon, further work is needed in order to identify the precise instructive cues that generate neural cells from many other tissue types, and whether or not the new cells are functionally normal. Furthermore, issues such as cell homogeneity and fusion need to be addressed further before the true potential of transdifferentiation can be known. Endogenous stem cells also reside in the neurogenic zones of the adult brain (ventricle lining and hippocampus). Further elucidation of the mechanisms that stimulate cell division and migration are required in order to learn how to amplify the small amount of new cells generated by the adult brain and to direct these cells to areas of injury or degeneration. Finally, a more fundamental understanding of brain injury and disease is required in order to circumvent local brain environmental restrictions on endogenous cell differentiation and survival.

Entities:  

Mesh:

Year:  2002        PMID: 12463763     DOI: 10.2165/00063030-200216060-00001

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


  9 in total

1.  Temporally induced Nurr1 can induce a non-neuronal dopaminergic cell type in embryonic stem cell differentiation.

Authors:  Kai-Christian Sonntag; Rabi Simantov; Kwang-Soo Kim; Ole Isacson
Journal:  Eur J Neurosci       Date:  2004-03       Impact factor: 3.386

2.  Transfection of neuroprogenitor cells with iron nanoparticles for magnetic resonance imaging tracking: cell viability, differentiation, and intracellular localization.

Authors:  Sosuke Miyoshi; Jennifer A Flexman; Donna J Cross; Kenneth R Maravilla; Yongmin Kim; Yoshimi Anzai; Junko Oshima; Satoshi Minoshima
Journal:  Mol Imaging Biol       Date:  2005 Jul-Aug       Impact factor: 3.488

Review 3.  Adult neural stem cells: response to stroke injury and potential for therapeutic applications.

Authors:  Basam Z Barkho; Xinyu Zhao
Journal:  Curr Stem Cell Res Ther       Date:  2011-12       Impact factor: 3.828

4.  Studies on the differentiation of dopaminergic traits in human neural progenitor cells in vitro and in vivo.

Authors:  Ming Yang; Angela E Donaldson; Cheryl E Marshall; James Shen; Lorraine Iacovitti
Journal:  Cell Transplant       Date:  2004       Impact factor: 4.064

Review 5.  Neurodegeneration and cell replacement.

Authors:  Brandi K Ormerod; Theo D Palmer; Maeve A Caldwell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-01-12       Impact factor: 6.237

6.  Rescue of radiation-induced cognitive impairment through cranial transplantation of human embryonic stem cells.

Authors:  Munjal M Acharya; Lori-Ann Christie; Mary L Lan; Peter J Donovan; Carl W Cotman; John R Fike; Charles L Limoli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

Review 7.  Microdialysis in central nervous system disorders and their treatment.

Authors:  David J McAdoo; Ping Wu
Journal:  Pharmacol Biochem Behav       Date:  2008-03-10       Impact factor: 3.697

8.  Regionally-specified second trimester fetal neural stem cells reveals differential neurogenic programming.

Authors:  Yiping Fan; Guillaume Marcy; Eddy S M Lee; Steve Rozen; Citra N Z Mattar; Simon N Waddington; Eyleen L K Goh; Mahesh Choolani; Jerry K Y Chan
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

9.  Hypoxia promotes dopaminergic differentiation of mesenchymal stem cells and shows benefits for transplantation in a rat model of Parkinson's disease.

Authors:  Yue Wang; Jian Yang; Haisheng Li; Xuan Wang; Lingling Zhu; Ming Fan; Xiaomin Wang
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.